XTL will gain efficacy and safety data to progress lead erythropoietin and antipsychotic candidates.
XTL Bio signed a strategic collaboration framework agreement with Clalit Research Institute and Mor Research Applications, which will provide the firm with clinical data and analyses to support XTL’s development of technologies and products licensed in from Mor. XTL says the deal means it can access safety and efficacy data to help in the design of clinical trials and the evaluation of new products. Clalit Research Institute and Mor Research Applications are the research arm, and technology transfer arm, respectively of Israel’s Clalit Health Services.
XTL’s lead recombinant human erythropoietin (rHuEPO) product for the treatment of multiple myeloma and its SAM-101 candidate for the treatment of psychotic disorders are in development under a license agreement with Mor. SAM-101 is based on a combination of existing antipsychotics together with another well-characterized compound, and has completed a Phase IIa study in Israel as a treatment for schizophrenia. The rHuEPO product is being prepared for Phase II clinical trials for the multiple myeloma indication.
XTL outlicensed its preclinical-stage Diversity Oriented Synthesis HCV small molecule inhibitors program to Presidio Pharmaceuticals in 2008.